Welcome to the 5th Macrophage-directed Therapies Summit
Capitalize on the Dynamic Plasticity of Macrophages Across Oncology, Autoimmunity & Inflammation
The spotlight is on macrophages due to their potential to provide a double-edged sword to fight oncology, autoimmunity and inflammation. Comprising up to 50% of tumor mass and playing a substantial role in tumor resistance, it is critical to optimize phenotypic modulation of macrophages, simultaneously unlocking optimal reprogramming in inflammatory disease.
The complexity of these innate cells creates unique targeting challenges but the 5th Macrophage-Directed Therapies Summit returned as the only forum to address bottlenecks in clinical translation, safety and heterogeneity to advance adoptive cell therapies, anti-CD47 and next-gen therapies from discovery and through the clinic
With 24+ expert speakers (including 14 new companies!) from Carisma Therapeutics, Shoreline Biosciences, Moderna, Boehringer Ingelheim, SIRPant and Macomics, we collaborated with this exclusive community to consolidate clinical progress, reviewed novel targets and turbocharged investment to capitalize on their potential and secure a successful future for macrophage-directed therapies.
2023 World-Class Speakers Included:
